Today, Triamcinolone aminobenzal benzamidoisobutyrate is a topic of great relevance and interest to a wide spectrum of the public. With the advancement of technology and globalization, Triamcinolone aminobenzal benzamidoisobutyrate has become an increasingly present topic in our lives, whether on a personal, professional or social level. Opinions on Triamcinolone aminobenzal benzamidoisobutyrate are varied and debated, making its study and understanding essential to understanding the world we live in. In this article, we will explore different perspectives on Triamcinolone aminobenzal benzamidoisobutyrate, analyzing its impact, evolution and relevance in different contexts.
Clinical data | |
---|---|
Trade names | Taucorten |
Other names | TBI-PAB; TBI/PAB; Tbi-Pab; 16α,17α-(4-Dimethylamino- benzyliden)triamcinolone 21-(β-benzoylamino)isobutyrate; 21-(3-(benzoylamino)-2-methyl-1-oxopropoxy)-16α,17α-(((4-(dimethylamino)phenyl)- methylene)bis(oxy))-9α-fluoro-11β-hydroxypregna-1,4-diene-3,20-dione |
Drug class | Corticosteroid; Glucocorticoid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C41H47FN2O8 |
Molar mass | 714.831 g·mol−1 |
3D model (JSmol) | |
| |
|
Triamcinolone aminobenzal benzamidoisobutyrate (TBI-PAB; brand name Taucorten) is a synthetic glucocorticoid corticosteroid which is no longer marketed.